| Biological Information | |
|---|---|
| Background Information: | CP 55,940 is a synthetic cannabinoid molecule developed by Pfizer that has similar but more potent effects to THC in behavioral and receptor binding tests. It is a cannabinoid receptor agonist, with EC50=0.2 and 0.3nM for CB1 and CB2 respectively. Is reported as both an agonist (EC50 = 5nM) and antagonist for GRP55 depending on the assay and dosages uses. Currently used to study the endocannabinoid system. Provided as 5 mg of dry powder. |
| Target Name: | CP 55,940 |
| Usage | |
| Product Type: | Control Ligands & Inhibitors |
| Application: | Drug Discovery & Development |
| Storage Conditions: | Store at -20°C. Please avoid multiple freeze/thaw cycles. |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
| Additional Information | |
| Brand: | DiscoverX |
CP 55,940
CP 55,940 is an agonist for CNR1 (CB1), CNR2 (CB2), and GPR55. This product is provided as 5 mg of dry powder.
Datasheets
92-1343 Datasheet
View Document